Adverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual Meeting
27 oct. 2022 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD
30 sept. 2022 16h45 HE
|
Adverum Biotechnologies, Inc.
- New data highlight that a single intravitreal injection of Ixo-vec can lead to stable and persistent aflibercept expression through three years resulting in fluid control supporting favorable vision...
Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit
23 sept. 2022 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Biotechnologies Announces Upcoming Data Presentation at AAO 2022
23 sept. 2022 08h00 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degeneration
14 sept. 2022 08h00 HE
|
Adverum Biotechnologies, Inc.
- LUNA trial will evaluate the 2x10^11 vg/eye (2E11) and a new lower 6x10^10 vg/eye (6E10) dose of Ixo-vec, with enhanced prophylactic steroid regimens in patients requiring frequent anti-VEGF...
Adverum Biotechnologies to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
08 sept. 2022 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
26 août 2022 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Biotechnologies Reports Second Quarter 2022 Financial Results
11 août 2022 16h05 HE
|
Adverum Biotechnologies, Inc.
- Dosing first Phase 2 LUNA trial participant with ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) on track for the third quarter of 2022 and preliminary data anticipated...
Adverum Biotechnologies to Participate in the 2nd Annual H.C. Wainwright Ophthalmology Virtual Conference
10 août 2022 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD
15 juil. 2022 08h32 HE
|
Adverum Biotechnologies, Inc.
- Study participants had an 81%-98% reduction in annualized anti-VEGF injections and demonstrated continuous aflibercept expression levels through three years - Mean best-corrected visual acuity...